Orilanolimab
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity[1][2].
Product Specifications
CAS Number
2066544-85-0
Product Name Alternative
SYNT001; ALXN1830
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/orilanolimab.html
Purity
99.9
Solubility
10 mM in DMSO
Smiles
[Orilanolimab]
Molecular Weight
(144.01 kDa)
References & Citations
[1]Blumberg LJ, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv. 2019 Dec 18;5 (12) :eaax9586. |[2]Blumberg L, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases[J]. Blood, 2017, 130: 3483.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-R415730-100MG 100 mg
2-Beta-D-Ribofuranosyl-4-thiazolecarboxylic Acid Ethyl Ester
Sign In for Pricing
View Details 